
Hot In The City: Why The Wrong Trees In The Wrong Places Matters
In the last days of last month, the death toll tripled in several major European cities in the face of sweltering heat. Milan, Paris, Barcelona and London were the worst hit. With more than two thirds of the world's population expected to live in cities by 2050, the race to cool them down is on. Tree planting has become an important part of urban heat mitigation efforts.
But a Cambridge University-led study shows that planting the wrong species or combinations of trees may not just reduce the benefits, but actually make things worse, elevating night time temperature.
The scientists found that planting trees in urban areas can lower pedestrian-height air temperature by up to 12 degrees centigrade (53.5 F). Introducing trees reduced the highest temperature in 83% of the cities studied. However, the extent will vary, depending on urban layout and species' traits.
'Our study challenges the common perception that trees are the ultimate panacea for overheating cities worldwide,' says Professor Ronita Bardhan from the University of Cambridge. 'Trees have a crucial role to play in cooling cities down, but we need to plant them much more strategically to get the best results.'
For instance, adds Bardhan, 'The cooling behaviour of a species in a rural environment may be very different in an urban setting. It also matters where these trees are placed. In more sparsely populated areas they will do well, but in heavily built-up areas, they won't.'
Until now, we've known relatively little about unique tree cooling mechanisms and how these interact with different urban features. Previous research has tended to focus on specific climates or regions, relying on fragmented case studies.
The first comprehensive global assessment of urban tree cooling has changed all that. The authors looked at a wide range of studies over 17 climates in 100 cities and regions for the period 2010 – 2023. Understanding why planting matters is the first step in getting green right.
How Trees Cool Cities
In daytime, trees help reduce temperature by blocking solar radiation while water evaporation and foliage alters the airflow. In some circumstances, however, the 'wrong' trees can also increase air temperature at night.
'When the aerodynamic resistance is high and the leaf stomata close, heat dissipation through transpiration is reduced, limiting the escape of heat energy,' Bardhan says. 'This typically happens at night. If there is a high humidity load, this humid-warm air can be trapped and re-circulate beneath the tree canopy.'
The scientists found that urban trees in compact settings are most effective in cooling cities in hot and dry climates but are less effective in hot, humid ones.
In tropical wet and dry climates with distinct wet and dry seasons, such as central Africa, parts of South America and northern Australia, trees can be very effective in cooling cities by day. In Nigeria, trees can cool temperatures by as much as 12 degrees centigrade. But at night, trees warmed cities the most, by up to 0.8 degrees.
Evergreens beside Dubai's International Financial Centre
A lush green canopy hangs over parts of Dubai City. Among the acacias, neem, olive, palm and other desert trees the evening air carries the scent of Indian jasmine. Last year the municipality planted 216,500 new trees as part of its ambitious 2023 Quality of Life Strategy.
Bardhan and colleagues found that trees performed well in arid climates such as Dubai's, cooling cities by just over 9 degrees and warming them at night by 0.4 degrees.
Elsewhere, however, in a tropical rain forest climate with higher humidity, daytime cooling was only 2 degrees. Closer to home, trees in more temperate climates, such as London, can cool cities by 6 degrees but warm them up by 1.5 degrees.
In many hot countries, trees tend to be evergreen. By including deciduous trees in the mix, the cooling effect can often be greater. Recent planting schemes in Saudi Arabia have incorporated deciduous as well as evergreens.
The nature of the local urban environment will have an impact on the potential cooling while the idea balance of temperate and deciduous trees will vary. Urban layouts such as London's are more likely to benefit from the inclusion of deciduous trees alongside evergreens, but to a lesser extent than in Saudi Arabia.
'If you plant deciduous trees in a densely populated part of London, they won't perform in the same way as in the wild,' Bardhan observes. 'It's also important where these trees are placed. Trees may perform well in sparsely populated areas, but in dense urban settings the limited cooling impact reflects failed design.
"To be effective for the climate, cities need to treat nature as a fundamental design variable, rather than an afterthought.'
Selecting the optimum type and location for trees in an urban setting is critical.
Few cities can afford projects on the scale of Dubai's and those who may need the right trees most because of global warming – are often the poorest.
Bardhan and her colleagues at Cambridge have come up with a solution. They are developing a prototype shading device, inspired by nature's way of cooling. It's already been tested out successfully in dense urban areas.
'It mimics everything that natural trees do,' explains Bardhan 'We can control humidity along with temperature unlike standard shading devices that only regulate temperature. The design also allows the release of trapped radiation at night, unlike a tree.'
The shading device can resemble a tree or take other forms, such as a vending cart. Rather than just being a luxury in affluent neighbourhoods, shade and cooling can come to schoolchildren and the most vulnerable communities at relatively low cost. As Bardhan says, it's climate action put into reality.
With the data provided by the Cambridge study, urban planners have an invaluable tool that could transform efforts to reduce heat.
You can see the cooling effect of trees in the cities researched on the interactive map here.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Associated Press
an hour ago
- Associated Press
CorTec Announces Neurotech Milestone: First Human Implantation of a Brain-Computer Interface made in Germany
FREIBURG, Germany, July 29, 2025 (GLOBE NEWSWIRE) -- CorTec GmbH, a pioneer in active implantable medical technologies, today announced the first human implantation of its proprietary BCI system, Brain Interchange™, marking a pivotal advance in translating laboratory research into real-world clinical applications. The procedure took place in late July at Harborview Medical Center (Seattle) under an FDA Investigational Device Exemption (IDE). Led by Principal Investigator Jeffrey G. Ojemann, MD, from the University of Washington School of Medicine in Seattle and Co PI Professor Steven C. Cramer from the University of California, Los Angeles, this trial will gather initial safety data and evaluate whether direct cortical electrical stimulation can enhance upper-limb motor recovery in stroke patients. The study is funded by the National Institutes of Health (NIH). 'We're thrilled to share that the implantation procedure was a success and, most importantly, the patient is in good condition and recovering well from the surgery. We're incredibly grateful for this initial outcome in our first study participant. Both the therapeutic strategy and the technology we are using are entirely novel. While we proceed with careful optimism, the potential benefits for patients are promising,' commented Jeffrey G. Ojemann, MD, Vice Chair and Professor of Neurological Surgery, University of Washington School of Medicine. This novel approach offers highly precise and personalized treatment for neurological conditions. The implant system continuously records brain activity, instantly interpreting signals and delivering targeted electrical stimulation in real time to enhance neuroplasticity, the brain's ability to reorganize neural networks. The study explores whether this can help the brain relearn lost functions, thereby accelerating and improving rehabilitation of patients. 'The first implantation of our BCI marks a milestone for European medical neurotechnology and underscores CorTec's emergence as Germany's first implantable BCI developer, ready to compete on the global stage,' said Dr. Frank Desiere, CEO of CorTec. 'Building on our extensive experience in developing advanced components and active implantable systems, our proprietary cutting-edge BCI system is now entering human clinical testing, aiming to help people affected by neurological diseases recover lost function and enhance their quality of life. We are proud of this new era of innovation and are committed to expanding the possibilities of neurotechnology to improve outcomes for patients.' Today in the US and Europe alone, 1.7 million people annually have a stroke that frequently involves loss of upper limb function. While physical therapy alone can help many patients regain function, it is sometimes not sufficient. Patients with a BCI may benefit from neuroplasticity-inducing stimulation during their rehabilitation. Regaining control of their upper limbs would enable patients to be more independent and have a better quality of life. 'This breakthrough opens the door to therapies that were once unimaginable,' added Dr. Martin Schuettler, CTO of CorTec. 'For the first time, our BCI system connects wirelessly to external hardware – no cables, no physical links. This approach is part of the transformation of neurological therapies worldwide, built on a technology platform that can be tailored to multiple neurological conditions, delivering real-time, patient-specific treatment. I'm incredibly proud of our team and our partners, in particular Jeffrey G. Ojemann and Jeffrey Herron of UW Medicine, who turned years of research into real hope for patients.' About CorTec CorTec GmbH, founded in 2010 in Freiburg, Germany is a pioneer in active implantable technologies and brain-computer interface (BCI) systems. The company is an established partner for medical device development and manufacturing for advanced components and active implantable systems. Its cutting-edge technologies drive innovation across the neurotechnology landscape—enabling researchers, clinicians, and industry leaders to unlock new clinical frontiers and engineer next-generation medical devices precisely tailored to targeted therapeutic indications. At the heart of CorTec's portfolio is the Brain InterchangeTM System, a fully implantable, wireless investigational device capable of long-term sensing and adaptive stimulation of neural tissue. The system is designed as a versatile platform to accelerate the development of novel, personalized neuromodulation therapies. CorTec's growth is supported by a strong network of strategic investors, including High-Tech Gruenderfonds, KfW, K&SW Invest, LBBW Venture Capital, Mangold Invest, M-Invest and Santo Venture Capital GmbH. For more information, visit Disclaimer: The research reported in this publication is supported by the National Institute of Neurological Disorders and Stroke of the National Institutes of Health under Award Number UH3NS121565. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.


Medscape
3 hours ago
- Medscape
EMA Turns Down Nurzigma for Huntington Disease
At its July 2025 meeting, the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended against granting marketing authorization in the European Union for Nurzigma (pridopidine, Prilenia Therapeutics) for treating adults with Huntington disease. Huntington disease is a rare, inherited, and fatal neurodegenerative disorder characterized by progressive motor, cognitive, and psychiatric symptoms. It affects approximately 5-10 individuals per 100,000 in the European population, which translates to an estimated 25,000-50,000 cases across the European Union. However, it currently lacks approved therapies to slow its progression. The available treatments only offer limited symptom control for Huntington disease-related complications, including chorea and behavioral issues. The active substance in Nurzigma, pridopidine, functions as an agonist of the sigma-1 receptor (S1R) within cellular structures, modulating pathways crucial for neuronal health and viability. This action on S1R is thought to ameliorate cellular dysfunctions associated with neuronal injury and Huntington disease, facilitating neurogenesis and attenuating oxidative stress, slowing neurodegenerative processes. Primary Endpoints Unmet in Trials Multiple clinical trials — including HART, MermaiHD, and PRIDE-HD — showed that, while pridopidine was generally safe and well tolerated, it failed to meet its primary motor endpoints. Despite this, post-hoc analyses suggested potential benefits in total functional capacity (TFC) in some patients. TFC scores assess how well individuals can perform day-to-day activities, including managing household tasks, finances, work, driving, and cooking. These findings led to the phase 3 PROOF-HD trial, which focused on functional outcomes rather than motor symptoms. However, the trial did not meet its primary endpoint, which was the change in TFC, in the overall study population. Post-hoc subgroup analyses showed potential benefits, particularly in patients not taking antidopaminergic medications. While these findings offered some insights into potential drug efficacy, the CHMP found them insufficiently robust and lacking in external validity. Despite setbacks, Prilenia Therapeutics and Ferrer said they are committed to advancing Nurzigma for Huntington disease, with new global studies planned to confirm its effectiveness. The companies have confirmed that the EMA's negative opinion on Nurzigma has no impact on patients currently enrolled in clinical trials or receiving the drug through compassionate use programs. Ongoing access and treatment protocols remain unchanged. However, patients should consult their clinical trial investigators for specific information regarding their continued treatment.
Yahoo
3 hours ago
- Yahoo
Gold Does Something Unexpected When Superheated Past Its Melting Point
Gold remains perfectly solid when briefly heated beyond previously hypothesized limits, a new study reports, which may mean a complete reevaluation of how matter behaves under extreme conditions. The international team of scientists behind the study used intense, super-short laser blasts to push thin fragments of gold past a limit known as the entropy catastrophe; the point at which a solid becomes too hot to resist melting. It's like a melting point, but for edge cases where the physics isn't conventional. In a phenomenon called superheating, a solid can be heated too quickly for its atoms to have time enter a liquid state. Crystals can remain intact way past their standard melting point, albeit for a very, very brief amount of time. Related: US Startup Claims It Can Make Gold Using Fusion Technology Typically, the entropy catastrophe is thought to be three times the standard melting point. Using a new method for calculating the energy of reflected X-rays to accurately measure absorbed heat energy, the team found gold could be heated 14 times that limit before it finally liquified. As surprising as it sounds, the results don't break any laws of thermodynamics – they just show that sometimes reactions happen too quickly for the laws of thermodynamics to apply. It seems the atoms inside gold have nowhere to move to for a brief period of time, allowing thermal energy to dissipate before the structure can give way. The researchers were able to reach 19,000 Kelvin (that's around 18,700 degrees Celsius or just over 33,700 degrees Fahrenheit), with the gold retaining its solid structure for more than 2 picoseconds (a picosecond is a trillionth of a second) – long enough to prompt the researchers to reconsider existing models. "This measurement not only surpasses the previously predicted bounds of the entropy catastrophe but also suggests a much higher threshold for the superheating of solids, thereby rewriting the fundamental understanding of the stability of the solid phase under extreme conditions," write the researchers in their published paper. The implications here are intriguing and exciting for physicists: it's possible that some solids don't have a melting point at all, at least when superheated for ultra-short periods of time. "Our experiments clearly demonstrate that the previously proposed limit of superheating can be exceeded by far if the material is heated fast enough," write the researchers. There are all kinds of areas where this new knowledge is going to be useful. Super-quick heating events happen everywhere from asteroid collisions deep in space, to nuclear reactors here on Earth, and scientists are now going to have a better understanding of what's happening within these events. The researchers want to see if other solids react in the same way as gold in future studies, as well as exploring the entropy catastrophe further: essentially redrawing the chart of when solids can no longer exist as solids. "Maybe we thought we solved it in the 1980s with this superheating limit, but now I think it's an open question again," physicist Thomas White, from the University of Nevada, told Alex Wilkins at New Scientist. "How hot can you make something before it melts?" The research has been published in Nature. Related News Humanity Has Dammed So Much Water It's Shifted Earth's Magnetic Poles We Have a New Record For The Most Accurate Clock Ever Built Quantum Teleportation Was Achieved Over Internet For The First Time Solve the daily Crossword